Infant Bacterial Therapeutics AB (publ) Interim Management Statement, January 1 – June 30, 2020
Message from the CEO   IBT is currently developing its drug candidate IBP-9414 to...
August 14, 2020
Annual General Meeting of Infant Bacterial Therapeutics
At the Annual General Meeting of Infant Bacterial Therapeutics AB (publ) on June 16, 2020, among...
June 16, 2020

Video presentation Annual General Meeting
Presentation for the Annual General Meeting by Infant Bacterial Therapeutics CEO, Staffan...
June 16, 2020
Notice to attend the Annual General Meeting of Infant Bacterial Therapeutics
Shareholders of Infant Bacterial Therapeutics AB (publ) are summoned to the Annual...
May 18, 2020

Infant Bacterial Therapeutics AB (publ) Interim Management Statement, January 1-March 31, 2020
Message from the CEO   IBT is currently developing its lead drug candidate...
May 11, 2020
Infant Bacterial Therapeutics publishes Annual Report for 2019
Infant Bacterial Therapeutics AB (publ) has today published the Annual Report for...
April 3, 2020

Infant Bacterial Therapeutics AB postpones Annual General Meeting
Due to the difficulty of gathering in larger groups, caused by the Corona Epidemic, IBT's...
April 3, 2020
Infant Bacterial Therapeutics AB (publ) Interim Management Statement, January 1 – December 31, 2019
Message from the CEO   IBT’s ongoing clinical phase III study with IBP-9414 has,...
February 11, 2020

Infant Bacterial Therapeutics AB (publ) announces that the Nomination Committee is appointed for the Annual General Meeting 2020
The Annual General Meeting of 2019 decided that the Nomination Committee would be...
November 11, 2019
Infant Bacterial Therapeutics AB (publ) Interim Management Statement, January 1 – September 30, 2019
Message from the CEO   In our previous quarterly report we were able to announce...
November 7, 2019

Lilian Wikström Ph.D. has requested to resign from the Board of Directors of Infant Bacterial Therapeutics AB
Lilian Wikström Ph.D. has requested to resign from the Board of Directors of IBT with...
November 5, 2019
Infant Bacterial Therapeutics AB (publ) Interim Management Statement, January 1 – June 30, 2019
Message from the CEO   On July 4 we were able to announce that the first patient...
August 21, 2019

Infant Bacterial Therapeutics has recruited the first patient in the pivotal Phase III clinical study
IBT has recruited the first patient in the Phase III pivotal clinical study, The...
July 4, 2019
FDA and Infant Bacterial Therapeutics agree on the design of Phase III study
IBT has for an extended time consulted with the US Food and Drug Administration (FDA) on...
May 19, 2019

Annual General Meeting of Infant Bacterial Therapeutics
At the Annual General Meeting of Infant Bacterial Therapeutics AB (publ) on May 6, 2019, among...
May 6, 2019
Infant Bacterial Therapeutics AB (publ) Interim Management Statement, January 1 – March 31, 2019
Message from the CEO   As previously communicated, IBT had a meeting with the Food and Drug...
May 6, 2019

Notice to attend the Annual General Meeting of Infant Bacterial Therapeutics AB (publ)
Infant Bacterial Therapeutics AB (publ) will hold its Annual General...
April 5, 2019
IBT publishes annual report for 2018
Today, Infant Bacterial Therapeutics AB (publ) publishes the Annual Report for the...
April 4, 2019

Infant Bacterial Therapeutics AB announces first distribution agreement
Infant Bacterial Therapeutics AB has today signed the first distribution agreement for...
March 5, 2019
Infant Bacterial Therapeutics AB (publ) Interim Management Statement, January 1 – December 31, 2018
Message from the CEO   IBT reached several significant milestones during 2018. IBT...
February 8, 2019

IBT appoints a new Director of Clinical Development
IBT welcomes Anna Olsson as Director of Clinical Development.   Anna has...
February 5, 2019
The Phase 3 study protocol is modified after IBT’s meeting with the FDA
Yesterday afternoon (EST) Infant Bacterial Therapeutics  had a meeting with the US Food...
November 21, 2018

Infant Bacterial Therapeutics AB (publ) Interim Management Statement, January 1 – September 30, 2018
Message from the CEO   The third quarter was dominated by extensive preparatory work...
November 14, 2018
IBTs Chief Scientific Officer invited to speak at NEC Society Symposium 2019
Infant Bacterial Therapeutics (IBT) Chief Scientific Officer, Eamonn Connolly, PhD has...
November 9, 2018

Infant Bacterial Therapeutics AB (publ) announces that the Nomination Committee is appointed for the Annual General Meeting 2019
The Annual General Meeting of 2018 decided that the Nomination Committee would be...
October 8, 2018
Infant Bacterial Therapeutics publishes prospectus in connection with the list change to Nasdaq Stockholm
On August 30, 2018, Infant Bacterial Therapeutics AB (publ) (”IBT” or the...
September 4, 2018

Infant Bacterial Therapeutics has been approved for listing on the main market of Nasdaq Stockholm
Nasdaq Stockholm’s Listing Committee has approved the admission of Infant Bacterial Therapeutics...
August 30, 2018
Infant Bacterial Therapeutics AB (publ) Interim Management Statement, January 1 – June 30, 2018
Message from the CEO   The second quarter was dominated by extensive preparatory...
August 16, 2018

IBT plans to start its phase 3 study in the second half of 2018 and contracts CRO
IBT has previously announced its plan to start the phase 3 study in the first half of 2018....
June 26, 2018
Annual General Meeting of Infant Bacterial Therapeutics AB
The Annual General Meeting of Infant Bacterial Therapeutics AB (publ) on May 15, 2018...
May 15, 2018

Infant Bacterial Therapeutics AB (publ) Interim Management Statement, January 1 – March 31, 2018
Message from the CEO   During the past year, IBT passed the most important...
May 15, 2018
Infant Bacterial Therapeutics AB Nomination Committee modifies its proposal to the Board of Directors
The IBT Nomination Committee presented its proposals to the AGM in April 2018, which will...
May 9, 2018

Notice to attend the Annual General Meeting of Infant Bacterial Therapeutics AB (publ)
Infant Bacterial Therapeutics AB (publ) will hold its Annual General...
April 16, 2018
Infant Bacterial Therapeutics publishes Annual Report for 2017
Today, Infant Bacterial Therapeutics AB (publ) publishes the Annual Report for the...
April 12, 2018

Infant Bacterial Therapeutics AB (publ) Interim Management Statement, January 1 – December 31, 2017
Message from the CEO  During the last year, IBT passed the most important milestones in...
February 28, 2018
Outcome of Infant Bacterial Therapeutics’ rights issue
To access the press release, please read the following disclaimer here.
February 2, 2018

New Project Manager at IBT
IBT welcomes Patrick Beke as Project Manager. Patrick has an education in biomedical...
January 17, 2018
Prospectus relating to Infant Bacterial Therapeutics’ rights issue published
To access the press release, please read the following disclaimer here.
January 10, 2018

Extraordinary general meeting in Infant Bacterial Therapeutics
The extraordinary general meeting of Infant Bacterial Therapeutics AB (publ) (“IBT”)...
January 8, 2018
Infant Bacterial Therapeutics presents data from its Safety and Tolerability Study in premature infants
Infant Bacterial Therapeutics and the principal investigator Dr. Josef Neu presented data...
December 11, 2017